SCHEMBL4257211

SCHEMBL4257211

Cn1nc(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3Cl)cc2)c(C(N)=O)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.53
FLT1 P17948 3/20 0.51
TEK Q02763 3/20 0.51
NTRK1 P04629 2/20 0.47
RET P07949 2/20 0.46
CSNK1E P49674 1/20 0.45
PDGFRB P09619 3/20 0.44
CHRNA7 P36544 1/20 0.44
LTK P29376 1/20 0.44
FLT3 P36888 1/20 0.44
CDK8 P49336 1/20 0.44
NTRK3 Q16288 1/20 0.44
MAPK14 Q16539 1/20 0.44
NTRK2 Q16620 1/20 0.44
AURKB Q96GD4 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260549 0.90 RET (0.57) RIPK1FLT1TEKNTRK1RET
SCHEMBL4262663 0.89 RIPK2 (0.58) RIPK1FLT1TEKNTRK1RET
SCHEMBL4257340 0.88 MEN1 (0.50) FLT1PDGFRBFLT3MAPK14CA12
SCHEMBL4257173 0.85 KDR (0.58) RIPK1FLT1TEKNTRK1RET
SCHEMBL6613292 0.81 KDR (0.55) RIPK1FLT1TEKNTRK1RET
SCHEMBL6614917 0.81 RIPK2 (0.51) RIPK1FLT1TEKNTRK1RET
SCHEMBL4257250 0.80 KDR (0.50) FLT1NTRK1RETPDGFRBFLT3
SCHEMBL4258858 0.79 RET (0.55) RIPK1FLT1TEKNTRK1RET
SCHEMBL6618727 0.78 EPHA3 (0.49) FLT1TEKNTRK1RETPDGFRB
SCHEMBL4258772 0.78 KDR (0.56) FLT1TEKNTRK1RETCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307097-B2 Chemical compounds SMITHKLINE BEECHMAN CORPORATION (US) 2007-12-11 US claimed
EP-1436265-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-12-15 EP claimed
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-10-07 US claimed
EP-1436265-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 EP claimed
WO-2003072541-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-04 WO claimed
US-20090012309-A1 CHEMICAL COMPOUNDS ADAMS JERRY LEROY 2009-01-08 US disclosed
US-7307097-B2 Chemical compounds SMITHKLINE BEECHMAN CORPORATION (US) 2007-12-11 US disclosed
EP-1436265-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-12-15 EP disclosed
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-10-07 US disclosed
EP-1436265-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 EP disclosed
WO-2003072541-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012309-A1 CHEMICAL COMPOUNDS CYP11B2, CYP3A43, CYP3A5 RIPK1 3166/4885FLT1 3586/4885TEK 4340/4885
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors ERBB2, RET, ERBB4 RIPK1 1256/4885FLT1 35/4885TEK 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.